ArticleFrontiers in pharmacology2026
Curcumin-berberine ointment based on multifunctional carrier accelerates wound healing in a translational porcine model of tail-biting injuries: a controlled study against oxytetracycline.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond susceptibility testing: traditional Chinese medicine-associated compounds as candidate antibiotic adjuncts in chronic-wound biofilms.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic wounds represent a significant clinical burden, with limited efficacy of conventional therapies, particularly in wounds complicated by necrosis and biofilms. This study evaluated the efficacy of MTC-U1 ointment based on a patented Multifunctional Carrier containing Methods: Fourteen Polish Large White fatteners with Grade 4 tail-biting injuries were randomized into two groups (n=7): MTC-U1 ointment or oxytetracycline spray (3.84%), applied twice daily for 21 days without surgical intervention. Wound healing was assessed using a modified Wilson scoring system (0-35 points). Secondary outcomes included infrared thermography, hematological parameters (neutrophils, haptoglobin), and local tolerance. Results: The healing time (from necrotic tissue sequestration to complete scab formation) was significantly shorter in the MTC-U1 group compared to the control group (9.57 ± 2.64 vs. 13.43 ± 2.88 days; Conclusion: The MTC-U1 ointment significantly accelerated chronic wound healing compared to antibiotic therapy, demonstrating anti-inflammatory effects confirmed by thermographic and hematological assessments. These findings support further preclinical validation and clinical trials in patients with hard-to-heal wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.